BiologicalDrug
Pegloticase clinical trials
Also written Krystexxa and Puricase.
- studies test it
- 16
- open now
- 1
- in phase 3
- 4
- first study started
- 2004
Keep track of what changes. Save the Pegloticase studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2006 | 2 |
| 2008 | 1 |
| 2012 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 4
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 12
Who runs them
Industry 13 · Other 3
Amgen (8) · Savient Pharmaceuticals (5) · University of Colorado, Denver (1) · M.D. Anderson Cancer Center (1) · John Sundy (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Pegloticase is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutRecruitingPhase 3AmgenNCT07388498Written as Pegloticase
- A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory GoutCompletedPhase 4AmgenNCT06229145Written as Pegloticase
- Uric Acid Lowering Trial in Youth Onset T2DCompletedPhase 2University of Colorado, DenverNCT03899883Written as Pegloticase 8 MG/ML [Krystexxa]
- A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)CompletedPhase 4AmgenNCT04762498Written as Pegloticase
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis SyndromeCompletedPhase 4M.D. Anderson Cancer CenterNCT04745910Written as Pegloticase
- Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving MethotrexateCompletedPhase 4AmgenNCT04511702Written as Pegloticase with MTX
- Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase MonotherapyCompletedPhase 4AmgenNCT04772313Written as Pegloticase
- Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled GoutCompletedPhase 4AmgenNCT03994731Written as Pegloticase
- Study of Pegloticase in Participants With Uncontrolled Gout Who Have Had a Kidney TransplantCompletedPhase 4AmgenNCT04087720Written as Pegloticase
- Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled GoutCompletedPhase 4AmgenNCT03635957Written as Pegloticase
- Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory GoutCompletedPhase 2John SundyNCT00111657Written as Pegloticase
- Study to Assess Pegloticase (KRYSTEXXA®) in Patients on HemodialysisCompletedPhase 1Savient PharmaceuticalsNCT01739660Written as Pegloticase
- A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional TherapyCompletedPhase 2Savient PharmaceuticalsNCT00080210Written as Puricase
- Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic GoutCompletedPhase 3Savient PharmaceuticalsNCT01356498Written as pegloticase
- Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout PatientsCompletedPhase 3Savient PharmaceuticalsNCT00675103Written as pegloticase 8 mg i.v.
- Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic GoutCompletedPhase 3Savient PharmaceuticalsNCT00325195Written as pegloticase
Given in every arm · 2 — Pegloticase is usual care beside what is tested
- REduCing Immunogenicity to PegloticasE (RECIPE) StudyCompletedPhase 2University of Alabama at BirminghamNCT03303989Written as Pegloticase 8 MG/ML [Krystexxa]
- Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering EffectCompletedPhase 2Ampel BioSolutions, LLCNCT02598596Written as Pegloticase
As the comparator · 1 — what is tested is compared with Pegloticase
Codes
What other systems call Pegloticase · ClinicalTrials.gg INT002958
- MeSH (NLM) C031545PegloticaseConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R581OT55EAPEGLOTICASEConfirmed FDA, NLM, Wikidata
- RxNorm 1011650Confirmed FDA, Wikidata
- Wikidata Q7160794pegloticaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97466PegloticaseOne source FDA
- DrugBank DB09208One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031545 | Pegloticase | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R581OT55EA | PEGLOTICASE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1011650 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7160794 | pegloticase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97466 | Pegloticase | One source FDA |
| DrugBank | DB09208 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.